Amplia Therapeutics (INNM.F) Stock Overview
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INNM.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.08 |
| 52 Week High | AU$0.27 |
| 52 Week Low | AU$0.028 |
| Beta | 0.67 |
| 1 Month Change | -20.00% |
| 3 Month Change | -48.39% |
| 1 Year Change | -41.73% |
| 3 Year Change | 28.00% |
| 5 Year Change | -38.46% |
| Change since IPO | -49.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| INNM.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 62.6% | 3.1% | 0.5% |
| 1Y | -41.7% | 3.9% | 20.1% |
Return vs Industry: INNM.F underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: INNM.F underperformed the US Market which returned 20% over the past year.
Price Volatility
| INNM.F volatility | |
|---|---|
| INNM.F Average Weekly Movement | 42.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INNM.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine INNM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.
Amplia Therapeutics Limited Fundamentals Summary
| INNM.F fundamental statistics | |
|---|---|
| Market cap | US$47.00m |
| Earnings (TTM) | -US$4.30m |
| Revenue (TTM) | US$2.48m |
Is INNM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNM.F income statement (TTM) | |
|---|---|
| Revenue | AU$3.78m |
| Cost of Revenue | AU$210.57k |
| Gross Profit | AU$3.57m |
| Other Expenses | AU$10.15m |
| Earnings | -AU$6.57m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 94.43% |
| Net Profit Margin | -173.69% |
| Debt/Equity Ratio | 0% |
How did INNM.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 08:46 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amplia Therapeutics Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Wakim | Bell Potter |